Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.004 AUD | 0.00% | -20.00% | +14.29% |
03-25 | Avecho Biotechnology Begins Patient Recruitment for Phase Three Anti-Insomnia Drug Trial | MT |
03-14 | Avecho to Push Forward with Phase III Trial of Anti-Insomnia Drug | MT |
Sales 2022 | 1.13M 735K 58.64M | Sales 2023 | 474K 308K 24.59M | Capitalization | 11.09M 7.22M 576M |
---|---|---|---|---|---|
Net income 2022 | -2M -1.3M -104M | Net income 2023 | -3M -1.95M -156M | EV / Sales 2022 | 23.3 x |
Net cash position 2022 | 1.22M 795K 63.46M | Net cash position 2023 | 5.33M 3.47M 277M | EV / Sales 2023 | 12.2 x |
P/E ratio 2022 |
-11.5
x | P/E ratio 2023 |
-2.31
x | Employees | 15 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 65.6% |
1 week | -20.00% | ||
Current month | -20.00% | ||
3 months | +14.29% | ||
Current year | +14.29% |
Managers | Title | Age | Since |
---|---|---|---|
Paul David Gavin
CEO | Chief Executive Officer | - | 31/12/01 |
Melanie Leydin
DFI | Director of Finance/CFO | 51 | 27/12/18 |
Roksan Libinaki
COO | Chief Operating Officer | - | 31/12/00 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ross Murdoch
BRD | Director/Board Member | - | 13/01/15 |
Director/Board Member | 60 | 12/01/20 | |
Gregory Collier
CHM | Chairman | - | 12/04/15 |
Date | Price | Change | Volume |
---|---|---|---|
30/04/24 | 0.004 | 0.00% | 3 147 162 |
29/04/24 | 0.004 | 0.00% | 55,888,860 |
26/04/24 | 0.004 | 0.00% | 328,140 |
24/04/24 | 0.004 | -20.00% | 3,223,219 |
23/04/24 | 0.005 | +25.00% | 2,406,841 |
Delayed Quote Australian S.E., April 30, 2024 at 07:10 am
More quotes1st Jan change | Capi. | |
---|---|---|
+14.29% | 8.32M | |
+1.77% | 42.86B | |
+12.24% | 42.74B | |
+43.91% | 41.36B | |
-8.83% | 27.68B | |
+7.44% | 25.15B | |
-23.01% | 18.63B | |
+30.56% | 12.37B | |
-1.82% | 11.92B | |
+8.35% | 11.21B |
- Stock Market
- Equities
- AVE Stock